pharmaphorum

AUGUST 24, 2020

She served as the Deputy Director (Acting) in the Office of Process and Facilities (OPF)/OPQ/CDER, responsible for new, generic, and biologic drug product quality review and facility assessment. Key sessions include: • Evaluating the ongoing Complications of Personnel Derived Contaminations. in Biology and Ph.D.

Contamination 52

Contamination In-Vitro Production Containment 52

The Pharma Data

MAY 4, 2021

Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Billion and Adjusted Diluted EPS (2) to a Range of $3.55 Now Anticipates Revenues of Approximately $26 Billion for BNT162b2, Reflecting 1.6 Billion Doses Expected to be Delivered in 2021 Under Signed Contracts as of Mid-April 2021. per share amounts). Reported Diluted EPS (1).

Vaccine 40

Vaccine Vaccination Production Sales 40

XTalks

SEPTEMBER 14, 2020

In the meantime, WHO Director-General, Tedros Ghebreyesus feels that “vaccine nationalism” may prove to be the undoing of the potential to halt the spread of COVID-19. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92